RBC Capital downgraded PTC Therapeutics (PTCT) to Sector Perform from Outperform with a price target of $91, up from $82. With the shares rallying nearly 75% in the past three months, RBC’s thesis has mostly played out, the analyst tells investors in a research note. The firm sees potential for additional momentum in the shares, but sees less room for significant additional appreciation following the recent rally.
Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PTCT:
- SanDisk Stock (SNDK) Jumps on S&P 500 Inclusion and Price Target Upgrades
- Closing Bell Movers: Zoom up 4% on earnings beat
- PTC Therapeutics to replace SanDisk in S&P 600 at open on 11/28
- Strong Market Penetration and Strategic Pricing Propel PTC Therapeutics to a Buy Rating
- PTC Therapeutics price target raised to $50 from $44 at Goldman Sachs